Cipla Share Price Target 2026: The Indian stock market benchmark indices, Sensex and Nifty 50, remained volatile this week driven by renewed concerns over rising crude oil prices and amid stalled US-Iran negotiations.

While some stocks have maintained their positions because of fundamentals and structural tailwinds, others are going into a tailspin.

Meanwhile, pharmaceutical major Cipla has received a bullish outlook from Citi following final approval from the United States Food and Drug Administration (USFDA) for generic Ventolin inhaler.

Founded in 1935, Cipla has a major presence across India, South Africa, and North America. The company has 46 advanced manufacturing hubs, producing over 1,500 products. Its key segments span across respiratory, anti-retroviral and cardiology. Recognised for its role in making HIV/AIDS treatment affordable and inclusive, Cipla has a market cap of over Rs 1 lakh crore.

At 9:33 AM today, shares of Cipla were trading at Rs 1,288.95, down 1.29 per cent from the previous close.

Citi's Target Price On Cipla

Citi has maintained a target price of Rs 1,530 on Cipla. The coverage was initiated after the company secured final approval from the USFDA for its generic version of Ventolin HFA, a widely used respiratory drug.

Cipla said its wholly owned subsidiary, Cipla USA Inc., has secured approval for Albuterol Sulfate Inhalation Aerosol (90 mcg), the first AB-rated generic therapeutic equivalent of Ventolin HFA, marketed by GlaxoSmithKline.

The drug is used to treat and prevent bronchospasm in patients aged four years and older, including those with obstructive airway diseases, and to treat exercise-induced bronchospasm.

Morgan Stanley On Cipla

Cipla Q3 Results FY2026

Cipla reported a sharp 57 per cent YoY decline in its consolidated net profit to Rs 676 crore for the third quarter of the current financial year (Q3 FY26). The company had posted a net profit of Rs 1,571 crore in the corresponding quarter last year.

Its revenue for the quarter under review came in flat at Rs 7,074 crore, compared with Rs 7,073 crore recorded in the same quarter of the previous financial year.

Cipla said that its EBITDA fell 37 per cent YoY to Rs 1,254 crore in the reporting three-month period, down from Rs 1,990 crore reported in the December quarter of FY25. The company's margin witnessed a sharp contraction of over 1,000 basis points, slipping to 17.7 per cent in the quarter.